### Groundbreaking Combination Therapy for Breast Cancer Treatment Recent clinical trials have revealed that the combination of Gilead's Trodelvy (sacituzumab govitecan-hziy) and Merck's Keytruda (pembrolizumab) significantly reduces the risk of disease progression in patients with advanced triple-negative breast cancer (TNBC). This innovative treatment approach has shown a **35% reduction** in the risk of disease worsening when compared to the standard treatment of Keytruda combined with chemotherapy. The findings are expected to transform treatment protocols for this aggressive cancer type, particularly for patients diagnosed with PD-L1+ metastatic TNBC [https://nypost.com/2025/05/31/health/breast-cancer-risk-cut-by-35-with-trodelvy-keytruda-trial, https://www.reuters.com/sustainability/boards-policy-regulation/gileads-trodelvy-with-keytruda-cuts-breast-cancer-risk-by-35-trial-2025-05-31]. ### Hypothesis and Structure of the Study 1. **Objective of the Trial**: The primary aim was to evaluate the efficacy of Trodelvy in combination with Keytruda as a first-line treatment for patients with PD-L1+ metastatic TNBC. 2. **Study Design**: This was a Phase 3 clinical trial comparing the new combination therapy against the standard treatment of Keytruda plus chemotherapy. 3. **Patient Population**: The trial focused on patients with inoperable locally advanced or metastatic TNBC, specifically those with a Combined Positive Score (CPS) of 10 or higher. 4. **Outcome Measures**: The main outcomes measured were the rates of disease progression and overall survival, with a focus on progression-free survival (PFS) [https://www.wallstreet-online.de/nachricht/19416360-trodelvy-plus-keytruda-reduces-risk-of-disease-progression-or-death-by-35-versus-keytruda-and-chemotherapy-first-line-pd-l1-metastatic-triple-negative-breast-cancer/2, https://www.rttnews.com/3543288/merck-s-keytruda-combo-cuts-risk-by-35-in-first-line-pd-l1-metastatic-tnbc-phase-3-study-confirms.aspx]. ### Supporting Evidence and Data - **Efficacy Results**: The combination therapy resulted in a **35% reduction** in the risk of disease progression or death (Hazard Ratio: 0.65, p<0.001) compared to the standard treatment [https://www.wallstreet-online.de/nachricht/19416363-keytruda-pembrolizumab-plus-trodelvy-sacituzumab-govitecan-hziy-reduced-risk-of-disease-progression-or-death-by-35-versus-keytruda-plus-chemotherapy-first-line-pd-l1-metastatic-triple-negative-breast-cancer-tnbc]. - **Progression-Free Survival**: Patients receiving the Trodelvy and Keytruda combination experienced an extended progression-free survival of **11.2 months** [https://www.stocktitan.net/news/GILD/trodelvy-plus-keytruda-reduces-risk-of-disease-progression-or-death-oh72xdl8qjyw.html]. - **Clinical Significance**: Experts believe these results could lead to a paradigm shift in the treatment of advanced TNBC, offering new hope to patients facing this challenging diagnosis [https://www.devdiscourse.com/article/health/3442381-breakthrough-in-breast-cancer-treatment-trodelvy-and-keytrudas-promising-combo]. ### Summary of Findings In summary, the combination of Trodelvy and Keytruda has demonstrated a **35% reduction** in the risk of disease progression or death in patients with advanced PD-L1+ metastatic TNBC. This significant finding is poised to change treatment practices and improve outcomes for patients diagnosed with this aggressive form of breast cancer. The key points are as follows: 1. **Innovative Treatment**: Trodelvy plus Keytruda represents a new standard of care for advanced TNBC. 2. **Clinical Trial Success**: The Phase 3 trial confirmed the efficacy of this combination therapy, showing substantial improvements in patient outcomes. 3. **Future Implications**: These results may lead to revised treatment guidelines and offer new hope for patients battling advanced breast cancer [https://money.usnews.com/investing/news/articles/2025-05-31/gileads-trodelvy-with-keytruda-cuts-breast-cancer-risk-by-35-in-trial, https://www.stocktitan.net/news/MRK/keytruda-pembrolizumab-plus-trodelvy-sacituzumab-govitecan-hziy-f9q1oqk772yy.html].